Across TCGA pan-cancer cohorts, LRBA Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LRBA data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LRBA Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated LRBA expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, LUAD, and SARC are the cancer types where LRBA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.917	0.594	.001	36	view →
LUAD	OS	Median	II,III,IV	0.004	0.751	<.001	18	view →
SARC	DFS	Median	All	0.205	0.617	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	III,IV	1.000	0.640	.007	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: LRBA tumor-vs-normal RNA expression · all LRBA data types